Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/27871
Title: | Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer | Authors: | SANCHEZ, Lizet MUCHENE, Leacky Lorenzo-Luaces, Patricia Viada, Carmen Rodriguez, Pedro C. Alfonso, Sailyn Crombet, Tania Neninger, Elia SHKEDY, Ziv Lage, Agustin |
Issue Date: | 2018 | Publisher: | W B SAUNDERS CO-ELSEVIER INC | Source: | SEMINARS IN ONCOLOGY, 45(1-2), p. 52-57 | Abstract: | Background: Progress in immunotherapy has revolutionized the treatment landscape for advanced lung cancer, with emerging evidence of patients experiencing long-term survivals. The goal of this study was to explore the existence of short- and long-term survival populations and to assess the effect of immunotherapy on them. Methods: Data from two randomized, multicenter, controlled clinical trials was used to evaluate the effect of two therapeutic vaccines (anti-idiotypic vaccine VAXIRA and anti-EGF vaccine CIMAVAX) on survival curves in advanced non-small cell lung cancer patients. Data were fitted to Kaplan-Meier, standard Weibull survival, and two-component Weibull mixture models. Bayesian Information Criterion was used for model selection. Results: VAXIRA did not modify, neither the fraction of patients with long-term survivals (0.18 in the control group v 0.19 with VAXIRA, P = .88), nor the median overall survival of the patients in the short-term survival subpopulation (6.8 v 7.8 months, P = .24). However, this vaccine showed great benefit for the patients belonging to the subpopulation of patients with long-term survival (33.8 v 76.6 months, P <.0001). CIMAVAX showed impact in the overall survival of both short- and long-term populations (6.8 v 8.8 months, P = .005 and 33.8 v 61.8 months, P = .007). It also increased the proportion of patients with long-term survival (from 0.18 to 0.28, P = .02). Conclusions: This study shows that therapeutic vaccines produce differential effects on short- and long-term survival populations and illustrates the application of advanced statistical methods to deal with the long-term evolution of patients with advanced lung cancer in the era of immunotherapy. (C) 2018 Elsevier Inc. All rights reserved. | Notes: | [Sanchez, Lizet; Lorenzo-Luaces, Patricia; Viada, Carmen; Rodriguez, Pedro C.; Crombet, Tania; Lage, Agustin] Ctr Mol Immunol, Clin Res Div, Calle 216 Esq 15, Havana 11600, Cuba. [Muchene, Leacky; Shkedy, Ziv] Hasselt Univ, Ctr Stat, Hasselt, Belgium. [Alfonso, Sailyn] Celestino Hernandez Robau Hosp, Villa Clara, Cuba. [Neninger, Elia] Hermanos Ameijeiras Hosp, Havana, Cuba. | Keywords: | long-term survival; non–small cell lung cancer; immunotherapy; survival mixture models;long-term survival; non-small cell lung cancer; immunotherapy; survival mixture models | Document URI: | http://hdl.handle.net/1942/27871 | ISSN: | 0093-7754 | e-ISSN: | 1532-8708 | DOI: | 10.1053/j.seminoncol.2018.04.005 | ISI #: | 000448095600007 | Rights: | Copyright 2018 Elsevier Inc. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2019 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
sanchez 1.pdf Restricted Access | Published version | 754.67 kB | Adobe PDF | View/Open Request a copy |
sanchez2018.pdf | Peer-reviewed author version | 735.13 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
2
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
4
checked on Sep 14, 2024
Page view(s)
68
checked on Sep 6, 2022
Download(s)
334
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.